Thursday, January 4, 2024

Medtronic And Cardiac Design Labs Collaborate To Launch Indigenously Developed Advanced Heart Rhythm Monitoring Technology

* Medtronic to become exclusive distributor of Padma Rhythms® monitoring device in India to enable early disease identification and management for patients from the comfort of their homes.

India Medtronic Private Limited, a wholly owned subsidiary of Medtronic plc (NYSE:MDT), today announced a strategic collaboration with Cardiac Design Labs (CDL) to launch, scale up, and expand access to CDL’s novel diagnostic technology, Padma Rhythms®, an external loop recorder (ELR) patch designed for comprehensive, long-term heart monitoring and diagnosis. As part of the collaboration, Medtronic will become the exclusive distributor of Padma Rhythms in India, while both Medtronic and CDL will jointly develop training and education programs to expand reach of the ELR technology across the country.

“We are excited to embark on this transformative journey with CDL to reshape cardiac rhythm monitoring in India,” said Michael Blackwell, vice president and managing director of Medtronic India. “Remote monitoring of cardiac diseases is a rapidly growing space and the inclusion of Padma Rhythms ELR patch provides us with an opportunity to serve more patients by expanding its reach across India.”

The ELR device combines the convenience of an external patch with the advanced capabilities of a Holter, ensuring accurate and insightful data for the monitoring period. It has been designed and manufactured in India by CDL and is powered by a first-of-its-kind connected platform for managing tests, data, algorithms, analysis, review, and reporting. CDL’s innovation includes wearables designed for use in sweat inducing conditions with dependable workflows and minimal interventions for use of devices. An automated data transfer mechanism allows physicians and technicians to access real-time test management dashboards and full disclosures on-demand.  

Cardiovascular disease (CVD) continues to be the leading cause of death globally and in India. A study by Global Burden of Disease puts the death due to CVD in India at 272 per 1 Lakh population as compared to the global average of 235.1

“We are thrilled to collaborate with Medtronic in our combined objective to alleviate the burden of heart rhythm disorders in India,” said Anand Madanagopal, founder and chief executive officer at CDL.  “The collaboration holds immense promise for the future of cardiac care in India. The launch of Padma Rhythms?marks the coming together of?a?decade of building an indigenous platform with strong R&D focus and interplay of technologies that can bring?a?tectonic shift?in the prevailing cardiac monitoring approaches.”

Proven with over two million hours of ECG from patients, CDL’s proprietary algorithms have been benchmarked against the best globally and remain core to their innovation and commitment to high standards of performance.2 This combined with the integrated platform assures test outcomes and accuracy in rhythm diagnosis. 

“Cardiac rhythm disorders can often exhibit subtle symptoms and can affect people of all ages and backgrounds. Affordable diagnostic solutions ensures that everyone, regardless of their socioeconomic status, can access essential diagnostic tools, leading to earlier detection and timely intervention,” said Dr. Devi Shetty, chairman of Narayana Health. “It is initiatives like these that will help address the growing burden of cardiovascular diseases in the country."

Padma Rhythms® ELR features dual ECG channels for precise abnormality detection, a high-resolution 16-bit ECG for accurate data analysis, and proprietary AI-powered algorithms for efficient monitoring. The device is disposable, easily activated, water-resistant, and breathable, ensuring comfort and reliable performance. Crafted with a focus on high fidelity and lightweight construction, it allows uninterrupted daily activities during continuous monitoring.

About Medtronic

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit and follow @Medtronic on Twitter and LinkedIn.

About CDL

Cardiac Design Labs (CDL) is on a mission to transform lives in early detection and diagnosis of diseases through innovation in healthcare. Powered by an indigenous platform for Advanced Cardiac Monitoring, Diagnostics and Vitals Monitoring, CDL is redefining healthcare experiences with deep innovation in devices and technology. Today this platform-driven innovation helps in proactive detection and treatment of cardiac conditions and health risks at efficiencies the world hasn't seen before. 

Its purpose is driven by a culture of R&D with relentless focus on clinical-grade performance and uncompromising design in products engineered to make an impact for patients in the toughest of conditions. Visit to learn how CDL is impacting lives and driving better outcomes for patients and physicians. 

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

All information provided herein is for general awareness purpose only and is not medical advice. Patients should talk to their doctor.

No comments:

Total Pageviews